Last reviewed · How we verify

NCT05325437: ELSDL

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients

Recruiting now NA Last updated 30 May 2025
What this trial tests

NA trial testing Laparoscopic splenectomy and azygoportal disconnection in Cirrhosis, Liver in 20 participants. Currently enrolling.

Timeline
1 March 2022
Primary endpoint
31 July 2025
31 July 2025

Quick facts

Lead sponsorNorthern Jiangsu People's Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 March 2022
Primary completion31 July 2025
Estimated completion31 July 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Northern Jiangsu People's Hospital

Who can join

18 and older, any sex, with Cirrhosis, Liver or Splenectomy; Status. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Laparoscopic splenectomy and azygoportal disconnection

Trials testing the same drug.

Other recruiting trials for Cirrhosis, Liver

Currently open trials in the same condition.

Other Northern Jiangsu People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05325437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing